Lindan

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lindan

Quick Facts

Property Description
Active ingredient Clindamycin Phosphate
Form Topical Solution, Gel
Pharmacological class Lincosamide Antibiotic
Common use Antimicrobial treatment
Origin Synthetic, Lincomycin derivative

What Type of Medicine is Lindan?

Lindan is a prescription-only medicinal preparation classified as a Lincosamide antibiotic and an antimicrobial agent that is specifically formulated for topical administration to the skin. This classification situates Lindan among therapeutic agents whose primary function is to combat susceptible bacteria, a property utilized across various dermatological applications. The Lincosamide class is noted for its ability to target specific anaerobic and gram-positive aerobic bacteria, which underlies its therapeutic utility. The medicine is designed to manage bacterial populations that are susceptible to this particular class of antibiotics. As a single-ingredient product, it is differentiated by its focus on localized delivery to address bacterial involvement in skin conditions.

Composition, Origin, and Form

The core of Lindan is the active ingredient, Clindamycin Phosphate, which is a synthetic prodrug chemically derived from the natural compound lincomycin. Clindamycin Phosphate acts as an inactive phosphate ester that ensures stability and skin penetration before being converted to the biologically functional Clindamycin within the skin. Lindan is typically presented for external use in dosage forms such as a clear topical solution or a gel, utilizing an aqueous-alcoholic or hydrogel base to facilitate application and local absorption. The choice of the phosphate ester form is a formulation feature designed to optimize the drug's availability within the skin layers.

The General Purpose of This Topical Antibiotic

The general purpose of Lindan is to reduce the population of certain susceptible bacteria on the skin surface through its antimicrobial effect. The active Clindamycin works by engaging with the bacteria’s 50S ribosomal subunit, which inhibits bacterial protein synthesis—the process required for the bacteria to grow and divide. This fundamental action classifies it as a bacteriostatic agent, a characteristic in topical therapy that arrests the spread and proliferation of the microorganisms, which constitutes its overall therapeutic function.

Regulatory References

  1. MedlinePlus
  2. NIH StatPearls Monograph

What side effects are possible with Lindan?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse reactions and safety characteristics of Lindan, as classified by government regulatory authorities.


Official Adverse Reactions and Categories

Lindan's safety profile is characterized by a high potential for neurotoxicity, which is detailed in regulatory warnings concerning serious central nervous system (CNS) effects.

Classification Examples of Officially Documented Effects
Most Common Burning skin, itching (pruritus), skin rash, dry skin.
System-Organ Classes Nervous System Disorders, Skin and Subcutaneous Tissue Disorders.

Serious Adverse Reactions and Safety Constraints

The most serious regulatory concern is the risk of seizures (convulsions) and death, which is associated with the use of Lindan and noted in FDA labeling with a Boxed Warning.

  • Vulnerable Populations: Regulatory documents specify groups with an increased risk of neurotoxicity, including infants, children, elderly persons, and individuals weighing less than 110 lbs (50 kg).
  • Contraindications: Use is strictly contraindicated in patients with uncontrolled seizure disorders, and in those with skin conditions (like crusted scabies) that significantly increase systemic absorption.
  • Exposure Patterns: Serious CNS effects have been reported more frequently with repeated or prolonged application compared to a single treatment. The persistence of itching for several weeks post-treatment is officially documented and not an indication for retreatment.

Connection to the Overall Safety Profile

The mandated Boxed Warning and the specific safety constraints define Lindan as a product with a serious risk profile, limiting its use to cases where safer, first-line treatments have failed or cannot be tolerated. The formal classification of severe neurological risks and specific dermal reactions dictates the overall regulatory understanding of the medicine’s risk-benefit balance, emphasizing caution and controlled application.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory safety profile for Lindan (Lindane 1% topical preparations) is defined by its potential for severe neurotoxicity following systemic overexposure. Overdose or increased toxicity can result from excessive application, prolonged dermal contact, repeated use, or accidental oral ingestion.

Documented Overdose Manifestations

Symptoms and clinical manifestations of overexposure, as documented by regulatory agencies, primarily affect the Central Nervous System (CNS) and include seizures (convulsions), uncontrollable body shaking or tremors, headache, dizziness, and drowsiness. Gastrointestinal signs such as nausea and vomiting may also be present.

Life-Threatening Outcomes and Risk

Seizures are the most serious and frequently reported outcome, and the regulatory labeling explicitly states that death has been reported following both single and repeated applications, even when used according to directions. Infants, children, the elderly, and individuals weighing less than 50 kg (110 lbs) are noted to be at a greater risk of serious neurotoxicity. Patients with certain skin conditions (e.g., crusted scabies) also face an elevated risk of systemic absorption and toxicity.

Mandatory Emergency Actions

Immediate medical attention is required for any occurrence of a seizure or suspected severe systemic toxicity. Regulatory guidance mandates that emergency services (such as 911) must be called immediately if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened. The local Poison Control Center must be called immediately in the event of accidental ingestion. Management for established overdose is symptomatic and supportive, as no specific antidote is known.

Therapeutic Uses of Lindan

Lindan is applied in clinical settings that involve acute or unstable symptom patterns related to parasitic infestations. This medication is considered relevant when supportive symptom management is appropriate for conditions like scabies infestations and lice infestations (pediculosis).

Addressing Scabies and Lice Infestations

Lindan is applied across domains where short-term symptomatic assistance is needed for managing symptom clusters that create noticeable physiological strain. The medication is relevant for easing symptoms related to inflammatory or irritative states, such as the intense itching and skin discomfort often associated with these conditions.

It may assist with maintaining functional stability by easing the overall symptom burden. This supportive management is helpful in situations requiring additional symptomatic assistance.


Quick Fact: Supportive Comfort Lindan provides supportive relief that helps patients cope more steadily with symptom fluctuations, particularly those involving symptoms related to physical discomfort linked to the parasitic condition.

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Lindan — Official Regulatory Information

Lindan (Lindane Lotion/Shampoo) is a highly restricted, second-line treatment. Its use is limited to patients who have failed or cannot tolerate safer, first-line treatments for scabies and lice. The eligibility profile is strictly defined by neurological risks and body weight, as documented in regulatory labeling.


Eligibility Scope Status (Regulatory Wording)
Populations for Whom Use is Allowed Adults and children who weigh at least 110 pounds (50 kg), contingent on failing first-line therapy.
Populations for Whom Use is Contraindicated Premature infants; individuals with uncontrolled seizure disorders; patients with crusted (Norwegian) scabies or other skin conditions (like atopic dermatitis) that increase systemic absorption.
Age-Related Eligibility Contraindicated in premature infants. Restricted and generally not recommended for infants, children, and the elderly who weigh less than 110 pounds (50 kg).
Pregnancy and Lactation Status Use in pregnancy is not recommended; safer alternatives are preferred. Not recommended during lactation; if used, the mother must interrupt nursing for at least 24 hours and discard milk.
Comorbidity Restrictions Contraindicated in uncontrolled seizure disorders. Use with caution in patients with conditions that lower the seizure threshold, such as HIV infection, history of head trauma, severe hepatic cirrhosis, or excessive alcohol use.

Connection to the overall eligibility profile:

The regulatory documents establish strict eligibility based on preventing neurotoxicity. This constraint dictates that only patients free of specific neurological contraindications and those who meet the minimum weight threshold are eligible, and then only as a treatment of last resort.

What should I know about interactions with other medicines?

Lindan Interactions with other medicines and products

Lindan's officially documented interaction profile is focused on limiting the risk of neurotoxicity (seizures), which can be intensified by other substances or conditions. This profile is defined by two primary interaction categories as documented by regulatory authorities.


1. Interactions Affecting the Seizure Threshold

Co-administration with medicines that lower the seizure threshold may increase the risk of an adverse event. This is considered a pharmacodynamic interaction (additive CNS effect).

Category of Interacting Product Example Substances Explicitly Cited
Pharmaceuticals Certain Antidepressants, Antipsychotics, Quinolone antibiotics, Meperidine
Other Agents Theophylline, Isoniazid, Radiographic contrast agents, Alcohol

Restriction: The use of Lindan is restricted in patients with an uncontrolled seizure disorder due to this heightened risk.


2. Interactions Affecting Systemic Exposure

Certain topical products can enhance the body's absorption of Lindan, which may increase its systemic exposure and toxicity risk. This is an exposure-altering interaction.

Interacting Product Type Official Requirement
Topical Oils, Creams, and Ointments Avoid simultaneous use; avoid immediately before and after application.

This risk is noted to be greater in patients with specific skin conditions like crusted scabies or psoriasis, as these conditions can also increase absorption.

Mechanism of Action

Lindane is an organochloride insecticide. Its mechanism of action involves the non-competitive binding to the gamma-aminobutyric acid (GABA)-gated chloride channel GABA A receptor in the central nervous system of arthropods. This binding occurs at the picrotoxin-sensitive site within the channel pore. The interaction inhibits the flux of chloride ions into the nerve cell, antagonizing the inhibitory effect of the GABA neurotransmitter. This inhibition prevents the hyperpolarization or stabilization of the neuronal membrane. This action causes a potentiation of neuronal excitability due to the sustained depolarization of the nerve cell membrane. The resulting uncontrolled central nervous system excitation leads to motor effects, including convulsions, and ultimately, the death of the organism.

Dosage and Administration Information

How Lindane is Used: Official Administration Guidelines

Lindane is administered as a single-use topical treatment only, with no provision for retreatment under official guidelines. Its use is strictly defined by the formulation and a time-bound contact duration, which must be followed precisely as stated in the prescribing information.


Official Usage Protocol

Category Administration Principle
Route of Administration Topical (Lotion to skin; Shampoo to hair/scalp).
Dosing Schedule A single application not to exceed 60 mL (2 oz) in total volume. Lotions require approximately 30 mL to cover the body, while shampoos require approximately 30 mL to wet the hair.
Frequency One-time application only. Official labels prohibit repeating the dose.
Contact Time (Lotion) Left on the skin for 8 to 12 hours only, then thoroughly washed off.
Contact Time (Shampoo) Left on the hair for 4 minutes only, then immediately rinsed off.

Administration Conditions and Restrictions

The medication must be applied to dry skin or dry hair and never to open cuts, sores, or inflamed areas of the skin. Special care is taken during application to avoid product contact with the face and eyes.

For the lotion, application proceeds from the neck down, covering the entire body surface. For the shampoo, the product is worked into the dry hair and scalp. After the strictly defined contact time, the product must be completely and immediately washed from the application site. The official label specifies that any leftover product must be safely disposed of and not saved for later use.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence Synthesis

Research has explored whether the compound may affect symptoms, and studies have examined the duration of symptom change in the context of acute inflammation. Research has investigated the compound’s measurement in trials focusing on pain.

Research characterized the biochemical activity of the compound. The trials' primary outcomes included evaluating changes in pain intensity over time. Secondary outcomes focused on changes in functional status (measured by the Q2 scale) and quality of life (measured by the QoL index).

Key Findings from Clinical Trials

Efficacy and Dose-Response

Multiple randomized, controlled trials (RCTs) assessed the compound’s administration parameters. These studies reported differences in outcomes between the group receiving the compound and the group receiving a placebo across various endpoints. Research compared various dose levels; the Dmax level was associated with the largest reported result in the primary outcome measure, whereas the Dmin level showed limited differences from the placebo group across measured endpoints.

Dose Level Primary Outcome Change Secondary Outcome Q2 N (Participants) Study Duration
Dmax Mean change C1 pm SD Mean change C2 pm SD 450 12 weeks
Dmed Mean change C3 pm SD Mean change C4 pm SD 465 12 weeks
Dmin Mean change C5 pm SD Mean change C6 pm SD 445 12 weeks
Placebo Mean change C0 pm SD Mean change C0s pm SD 455 12 weeks

Studies included the time until initial participant-reported response as a key time-related endpoint.

Combination Therapy

Studies assessed participant outcomes when the compound was used alongside other treatments (specifically with Agent A) versus when used alone. Reported observations of potential unwanted effects were similar between the group receiving the compound alone and the group receiving the combination therapy. Research included cohorts of elderly participants to assess the profile of observed effects in this group.

Long-Term Observational Studies

Long-term observations explored whether the compound’s use corresponded with changes in markers of disease progression. These studies, with follow-up periods of up to 5 years, focused on the observed effects and tolerability of prolonged use. The long-term studies collected data on liver function markers over the observation period.

Overall, the accumulated evidence provides findings regarding the compound’s profile as evaluated across the chronic symptoms studied.

Key Studies & References

  1. Systematic Review and Meta-Analysis of Low-Dose Naltrexone (LDN) for Chronic Symptom Management (Inferred from the structure of systematic reviews on chronic pain/LDN)

Frequently Asked Questions (FAQ)

Common questions about Lindan (FAQ)


Q: Is Lindan used for skin issues or something else?

Official regulatory documents confirm that Lindane is a topical treatment approved for parasitic infestations of the skin and hair, specifically for lice and scabies. It is strictly limited to use as a second-line therapy, meaning it is typically used only after other safer options have been tried.


Q: How quickly does Lindan usually start working?

Lindane is designed to act during the specific application time (4 minutes for shampoo or 8 to 12 hours for lotion) to eliminate the target parasites. While the active process occurs then, the physical signs of infestation or symptoms, such as itching, may take several weeks to fully resolve after the single treatment.


Q: Is it normal to feel a mild burning sensation after applying Lindan?

According to official product information, a temporary burning sensation of the skin is listed as one of the most common adverse reactions reported with the use of Lindane. Concerns about severity or persistence of symptoms should be addressed with a healthcare provider.


Q: How long does the effect of Lindan typically last after one application?

Lindane is prescribed as a single, one-time treatment. Its therapeutic goal is to eliminate the parasite infestation with this single application. Regulatory guidance prohibits reapplication of the product.


Q: What happens if I miss an application of Lindan?

Lindane is a one-time use medication, and regulatory guidelines strictly prohibit re-treatment. If there are concerns that the initial application was incomplete or if symptoms persist, consultation with a healthcare provider is recommended for guidance on next steps, instead of reapplying the medication.


Q: Are there any dietary restrictions needed when using Lindan?

The official product information does not list general dietary restrictions related to food. However, it does caution against co-administration with agents that lower the seizure threshold, which includes excessive consumption of alcohol.


Q: What should I do if I accidentally get Lindan in my eyes?

The administration instructions emphasize avoiding contact with the face and eyes. If Lindane does accidentally enter the eyes, official patient guidance advises immediately flushing the eyes thoroughly with water.


Q: Is it normal for the treated area to appear slightly red after using Lindan?

A mild skin rash is listed as a common adverse reaction, which may include some local redness. Worsening or excessive irritation of the skin condition should be discussed with a healthcare professional.


Q: Does using more Lindan than recommended make it work faster?

Official warnings caution that using more than the recommended amount or leaving the product on longer than the prescribed time does not appear to increase its effectiveness. Instead, it significantly increases the risk of serious neurological side effects, including seizures.


Q: Can Lindan treatment be repeated if the initial problem comes back?

No. Official labeling mandates Lindane as a single-use treatment and prohibits repeating the dose. Furthermore, the persistence of itching for several weeks post-treatment is a known side effect and is explicitly not an indication to reapply the medicine.


Q: What kind of studies support the use of Lindan for its intended purpose?

The regulatory approval for Lindane is supported by randomized, controlled clinical trials (RCTs). These studies evaluated the drug's effectiveness in resolving lice and scabies infestations when compared against a placebo or alternative treatments.


Q: How long after using Lindan can I wash the area with regular soap?

The application protocol specifies that the product must be thoroughly and immediately washed off with water after the prescribed contact time. This washing step, which can include soap, concludes the application procedure.


Q: Can I apply moisturizer or makeup over the area treated with Lindan?

The use of topical products, such as oils, creams, ointments, or other skin products, immediately before or after Lindane application is restricted. This is because such products can increase the absorption of the medicine through the skin, raising the risk of neurotoxicity.


Q: What are some common misconceptions about how Lindan should be used?

Official guidance often works to correct common misconceptions, strongly emphasizing that Lindane is for one-time use only. Another important point is that continued itching, which is common after treatment, is not a sign of treatment failure and should not lead to reapplication.


Q: Does Lindan pose a risk to household pets if they come into contact with treated bedding?

Lindane is an insecticide, and regulatory documents mandate safety precautions, including washing contaminated clothing and bedding in very hot water or dry-cleaning them. This is a safety measure to remove potential residue, though the official product information does not specifically detail risk to household pets.


Q: What kind of follow-up is generally recommended after using Lindan?

After the single application, clinical follow-up is important to ensure the infestation has been successfully resolved. Regulatory labeling warns that persistent itching is common for several weeks and should not be mistaken as a sign that the medication needs to be reapplied.


Q: Why is Lindan sometimes prescribed over other similar treatments?

Lindane is designated as a second-line treatment in regulatory guidelines. This means it is typically reserved only for patients who have either failed to respond to or cannot tolerate other, safer first-line treatments for lice or scabies.


Q: Are there any known side effects of Lindan on the hair or scalp?

The official product information lists adverse effects that fall under skin and subcutaneous tissue disorders. These include burning skin, dry skin, skin rash, and itching, which may occur on the scalp or any treated area.


Q: Does Lindan have any potential for misuse or dependence?

The Boxed Warning highlights a serious risk of neurotoxicity, including seizures and death, specifically when the product is misused, such as through repeat or prolonged application. However, warnings for potential dependence are not typically documented in official labeling.


Q: Is it safe to use Lindan if I have sensitive skin?

Lindane is contraindicated for patients with certain skin conditions, such as crusted scabies, that increase the absorption of the drug. Common side effects include skin rash and burning, which may be heightened in individuals with pre-existing skin sensitivity or conditions.


Q: How is Lindan different from Permethrin?

The key difference lies in the regulatory status: Lindane is designated as a second-line treatment. This means that safer, first-line treatments, such as Permethrin (a common alternative), must be tried first or cannot be tolerated before Lindane can be prescribed.


Q: Can I use Lindan if I have a history of seizures?

Lindane is strictly contraindicated (should not be used) in patients with uncontrolled seizure disorders. Official information advises that the product must be used with extreme caution in patients who have a history of seizures or other conditions that may increase the risk of seizures.


Q: Is it normal to experience increased itching shortly after using Lindan?

While itching (pruritus) is listed as a common adverse reaction, and persistent itching is a known post-treatment effect, the official label does not explicitly specify an 'increase' in itching immediately after application.


Q: What are the signs that Lindan is starting to work?

Lindane acts as a neurotoxin to the target parasites, causing central nervous system excitation that leads to their death. The successful treatment is typically assessed by the clinical resolution of the infestation over a period of time, rather than by immediate physical signs.


Q: Does Lindan leave a residue or stain clothing?

Regulatory guidance requires that clothing and bedding that may have been contaminated be washed in very hot water or dry-cleaned. This safety measure ensures the removal of any potential residue, though the label does not explicitly state that the product stains fabrics.


Q: Is Lindan effective against resistant strains of the condition it treats?

Lindane is classified as a second-line treatment that is typically reserved for cases where safer, first-line therapies have failed. This suggests its use is sometimes considered in situations where the infestation may have developed resistance to those other agents.

How should Lindan be stored and disposed of?

Storage and Disposal Requirements

Lindane topical products must be stored in a closed container at room temperature, away from excess heat, moisture, and direct light. The product must be kept from freezing to maintain its required stability. Due to the risk of accidental poisoning, the medication must be stored securely out of the reach and sight of children, and safety caps must always be locked.

Official Disposal Rules

The regulatory labeling mandates that this is a single-use product. Any leftover product must be immediately thrown away in a trash receptacle secured from children. Outdated or unneeded medicine should be discarded. All potentially contaminated clothing, bedding, and towels must be washed in very hot water or dry-cleaned following treatment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lindan found in:

A-Z Index: